Connect with pharmaceutical and healthcare regulatory authorities around the world via this directory.
Connect with pharmaceutical and healthcare regulatory authorities around the world via this directory.
Read this article in Pharmaceutical Technology's Regulatory Sourcebook March 2021 eBook.
FDA Approves Novartis Oral Treatment for Adults with C3 Glomerulopathy
March 25th 2025Fabhalta (iptacopan) received a positive opinion for treatment of C3G from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and has been approved twice before by FDA.